Brazil Approves New Pill for Rare Heart Disease

Brazilian health officials just approved a new treatment for a rare heart disease that has left patients with few options for decades.

The medication, sold as Beyonttra in Brazil, treats transthyretin amyloid cardiomyopathy, a progressive disease where misfolded proteins build up in the heart. This buildup causes heart walls to thicken and stiffen, making it harder to pump blood and leading to irregular heartbeat, swelling, and severe fatigue.

"This marks an important step forward for Brazilian patients living with ATTR-CM," said Dr. Jonathan Fox, chief medical officer at BridgeBio, the therapy's developer. The disease often progresses faster and more aggressively than other heart conditions, yet diagnosis and treatment have historically been delayed.

The approval comes from results of a global trial involving more than 600 adults across 18 countries. Patients who took the twice-daily pill saw a 23% reduction in death from any cause and a 50% drop in heart-related hospitalizations compared to those receiving a placebo.

Perhaps most remarkably, these benefits appeared in just three months. Patients also walked farther in fitness tests, saw improvements in blood markers of heart stress, and reported better quality of life.

The medication works by stabilizing the transthyretin protein before it can break apart and form the toxic clumps that damage heart tissue. By keeping the protein stable, the drug slows disease progression and eases symptoms.

The Ripple Effect

Beyonttra's approval in Brazil reflects a growing global recognition of this once-overlooked disease. The same medication is already available in the United States (as Attruby), the European Union, the United Kingdom, and Japan, with applications pending in other countries.

Dr. Fábio Fernandes, who led part of the trial at the University of São Paulo Medical School, called the results "a major advance for patients with ATTR-CM, who often face an earlier and more aggressive course of disease." For too long, he noted, this community has lived with limited options and delayed diagnosis.

BridgeBio will partner with Biopas, a company specializing in bringing innovative medicines to Latin America, to make the treatment available in Brazil starting later this year. The collaboration aims to ensure patients in underserved regions can access life-changing care.

For families who have watched loved ones struggle with this devastating disease, the approval brings something that's been in short supply: genuine hope for a longer, healthier life.